Holen Sie sich die Stockscreener-App
30.68
0.29%
-0.2082
Schlusskurs vom Vortag:
$30.89
Offen:
$30.92
24-Stunden-Volumen:
1.85M
Relative Volume:
0.80
Marktkapitalisierung:
$3.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-7.4005
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
+8.45%
1M Leistung:
-5.95%
6M Leistung:
-15.08%
1J Leistung:
+14.16%
1-Tages-Spanne:
$30.04
$31.00
1-Wochen-Bereich:
$28.61
$31.00
52-Wochen-Spanne:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
30.69 | 3.59B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
If Viking Therapeutics Is Acquired, Here’s Who Wins - Yahoo Finance
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - AOL.com
Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings? - simplywall.st
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool
Don't buy Viking Therapeutics stock until you read this - MSN
Don't Buy Viking Therapeutics Stock Until You Read This - The Motley Fool
Could Viking Therapeutics Be the Next Eli Lilly? - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent Returns - Yahoo Finance
Is Viking Therapeutics a Top Takeover Target? - The Motley Fool
Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors? - simplywall.st
Viking Therapeutics, Inc. Stock 12‑Month Price Target Raised to $95.4, Implies 209% Upside - TradingView
Viking Therapeutics Analyst Ratings and Price Targets | NASDAQ:VKTX - Benzinga
2 Stocks That Could Realistically Double by 2030 - The Motley Fool
VKTX Technical Analysis | Trend, Signals & Chart Patterns | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics faces timeline risk, but upside could be huge - MSN
Viking Therapeutics to Participate at Upcoming Investor Conferences - StreetInsider
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Globe and Mail
Three Biotechs That Are Top Takeover Targets - 24/7 Wall St.
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Oral VK2735 Obesity Data Release - Yahoo Finance
Avoiding Lag: Real-Time Signals in (VKTX) Movement - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story - simplywall.st
VKTX Q1 earnings miss on higher phase 3 development costs - MSN
Viking Therapeutics (VKTX) Valuation Revisited After New VK2735 Phase 2 Obesity Data Spurs Investor Interest - simplywall.st
Viking Therapeutics (VKTX) Reveals Promising Phase 2 Trial Resul - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTU - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Patients on experimental obesity drug lost up to 26.6 lb in 13 weeks - Stock Titan
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss - Investing.com India
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss By Investing.com - Investing.com South Africa
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jan 05 '26 |
Sale |
32.90 |
57,661 |
1,896,969 |
189,891 |
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):